Benzinga | Jun 30, 2021 04:40AM EDT

Keybanc Maintains Overweight on Avid Bioservices, Raises Price Target to $28

Keybanc analyst Paul Knight maintains Avid Bioservices (NASDAQ:CDMO) with a Overweight and raises the price target from $22 to $28.